Coya Therapeutics Announces $46.8M Cash Balance, Extends Runway to H2 2027, and Targets Q1 2027 for Phase 2 Data
COYA is trading near its 52-week low of $3.94 (12% above the low).
Summary
Coya Therapeutics reported an unaudited cash balance of $46.8 million as of December 31, 2025, projecting a cash runway into the second half of 2027. The company also expects topline data from its ALSTARS Phase 2 trial in the first quarter of 2027.
Key Events · Financing and Capital Events · COYA
-
Strong Cash Position Reported
Coya Therapeutics announced an unaudited cash balance of $46.8 million as of December 31, 2025.
-
Extended Cash Runway
The company projects this cash balance will fund its operations into the second half of 2027, significantly extending its financial stability.
-
Key Clinical Data Expected
Topline data from the ALSTARS Phase 2 trial is anticipated in the first quarter of 2027, marking a significant upcoming milestone.
Analysis · COYA · Life Sciences
Coya Therapeutics' announcement of a substantial cash balance and an extended operational runway into the second half of 2027 significantly de-risks the company's financial position. For a life sciences company, this reduces immediate concerns about capital raises and potential dilution, providing stability to advance its clinical programs. The clear timeline for the ALSTARS Phase 2 trial data readout in Q1 2027 also provides investors with a critical catalyst to monitor, as successful clinical data is paramount for biotech valuation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COYA was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $89.6M. The 52-week trading range was $3.94 to $8.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.